trending Market Intelligence /marketintelligence/en/news-insights/trending/QGrIlC--tcv_pGZb6uvbgw2 content esgSubNav
In This List

Nemus Bioscience considering legal options against Schneider Brothers

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints

Blog

Shore Capital is Now Available in S&P Global’s Aftermarket Research Collection


Nemus Bioscience considering legal options against Schneider Brothers

Nemus Bioscience Inc. said it is considering legal options against Schneider Brothers Ltd. and its affiliates for failing to provide funding to the company under a private placement agreement.

Schneider Finance LLC had agreed to invest $20 million in Nemus in May via the purchase of 1 million series E preferred stock. The placement was guaranteed by SB Securities Ltd., another affiliate of Schneider Brothers.

Schneider Finance failed to close the transaction on July 10, as required by the agreement, while SB Securities failed to pay the $20 million within 90 days of notice of Schneider Finance's default, Nemus said in a statement.

Nemus has engaged Haynes and Boone LLP to advise it on legal rights against the Schneider Brothers and its affiliates.

Nemus had about $108,859 in cash as of June 30.